Rare germline ATM variants predispose to secondary cancer in chronic lymphocytic leukaemia patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F25%3A10159354" target="_blank" >RIV/00098892:_____/25:10159354 - isvavai.cz</a>

Výsledek na webu

<a href="https://onlinelibrary.wiley.com/doi/10.1002/cac2.70010" target="_blank" >https://onlinelibrary.wiley.com/doi/10.1002/cac2.70010</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/cac2.70010" target="_blank" >10.1002/cac2.70010</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Rare germline ATM variants predispose to secondary cancer in chronic lymphocytic leukaemia patients

Popis výsledku v původním jazyce

In this monocentric study, we aimed to assess whether patients with CLL carrying rare germline variants in ATM have a higher risk of familial CLL or a higher risk of cancer in first-degree relatives than patients without these variants. Next, we aimed to assess whether patients carrying rare ATM variants develop secondary cancer or develop CLL at an earlier age than patients without these variants, and whether these variants influence the time to first treatment (TTFT) and overall survival (OS) in patients with CLL. In this large cohort, we also sought to confirm our previous observation that rare variants in ATM are associated with the development of IGHV-unmutated CLL, which has a worse prognosis compared to IGHV-mutated disease.

Název v anglickém jazyce

Rare germline ATM variants predispose to secondary cancer in chronic lymphocytic leukaemia patients

Popis výsledku anglicky

In this monocentric study, we aimed to assess whether patients with CLL carrying rare germline variants in ATM have a higher risk of familial CLL or a higher risk of cancer in first-degree relatives than patients without these variants. Next, we aimed to assess whether patients carrying rare ATM variants develop secondary cancer or develop CLL at an earlier age than patients without these variants, and whether these variants influence the time to first treatment (TTFT) and overall survival (OS) in patients with CLL. In this large cohort, we also sought to confirm our previous observation that rare variants in ATM are associated with the development of IGHV-unmutated CLL, which has a worse prognosis compared to IGHV-mutated disease.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cancer Communications

ISSN

—

e-ISSN

2523-3548

Svazek periodika

45

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

4

Strana od-do

669-672

Kód UT WoS článku

001442771400001

EID výsledku v databázi Scopus

2-s2.0-105000397619